Publisher's Note
Liver Cancer 2020;9:231 (Source: Liver Cancer)
Source: Liver Cancer - June 3, 2020 Category: Cancer & Oncology Source Type: research
Better Efficacy of Ramucirumab in Japanese Patients than in the Global Population with Unresectable Hepatocellular Carcinoma
Liver Cancer 2020;9:232 –244 (Source: Liver Cancer)
Source: Liver Cancer - May 29, 2020 Category: Cancer & Oncology Source Type: research
A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements
The Asia-Pacific Primary Liver Cancer Expert (APPLE) Consensus Statement on the treatment strategy for patients with intermediate-stage hepatocellular carcinoma (HCC) was established on August 31, 2019, in Sapporo, Hokkaido during the 10th Annual APPLE Meeting. This manuscript summarizes the international consensus statements developed at APPLE 2019. Transarterial chemoembolization (TACE) is the only guideline-recommended global standard of care for intermediate-stage HCC. However, not all patients benefit from TACE because intermediate-stage HCC is a heterogeneous disease in terms of tumor burden and liver function. Ten i...
Source: Liver Cancer - May 13, 2020 Category: Cancer & Oncology Source Type: research
Mortality after Transplantation for Hepatocellular Carcinoma: A Study from the European Liver Transplant Registry
Conclusions: Using PS calibration, we showed that HCC in non-cirrhotic liver has similar overall mortality, but higher HCC-specific mortality. This may be a result of a more aggressive cancer form in the non-cirrhotic liver as higher mortality could not be explained by tumour characteristics or other prognostic variables.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - May 12, 2020 Category: Cancer & Oncology Source Type: research
Tenofovir Treatment Has Lower Risk of Hepatocellular Carcinoma than Entecavir Treatment in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis
Conclusions: Evidence to date suggests that TDF treatment is associated with significantly fewer cases of HCC when compared to ETV.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - May 5, 2020 Category: Cancer & Oncology Source Type: research
Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma
Conclusion: Lenvatinib had potential benefits for patients with advanced HCC with second- or later-line therapies and a high burden of intrahepatic lesions. Dose modification should be paid increased attention among patients with poor liver function, such as Child-Pugh class B patients.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - May 5, 2020 Category: Cancer & Oncology Source Type: research
Irradiation-Related Lymphopenia for Bone Metastasis from Hepatocellular Carcinoma
Conclusion: TRL was observed in patients receiving RT for bone metastasis from HCC, and it was associated with poor survival. The percentage of active bone marrow within the RT field significantly affected TRL development. The results suggest that a new strategy is required to prevent TRL.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - June 21, 2019 Category: Cancer & Oncology Source Type: research
B-Mode Ultrasonography versus Contrast-Enhanced Ultrasonography for Surveillance of Hepatocellular Carcinoma: A Prospective Multicenter Randomized Controlled Trial
Conclusion: Kupffer phase CEUS surveillance with Sonazoid is extremely useful for the early detection and confirmation of HCC using a reinjection technique. Kupffer phase CEUS with Sonazoid contrast combined with the reinjection technique is, therefore, recommended as first-line screening tool for HCC in patients with liver cirrhosis, especially those with very coarse liver parenchyma.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - June 6, 2019 Category: Cancer & Oncology Source Type: research
Systemic Treatment Options in Hepatocellular Carcinoma
Background: Patients with advanced hepatocellular carcinoma (HCC) typically have poor survival outcomes. Until recently, sorafenib was the only systemic therapy option available and no agents were approved after sorafenib failure. However, rapid changes are beginning to emerge in the treatment landscape of advanced HCC, with approvals of regorafenib, nivolu mab, lenvatinib, pembrolizumab, and cabozantinib and positive phase II/III clinical trial results with other agents.Summary: Here, we provide a comprehensive overview of the clinical trial data of systemic agents that are currently approved for advanced HCC (sorafenib...
Source: Liver Cancer - May 29, 2019 Category: Cancer & Oncology Source Type: research
APPLE News
Liver Cancer 2019;8:218 –218 (Source: Liver Cancer)
Source: Liver Cancer - May 17, 2019 Category: Cancer & Oncology Source Type: research
The APPLE Association President's Message
Liver Cancer 2019;8:219 –219 (Source: Liver Cancer)
Source: Liver Cancer - May 17, 2019 Category: Cancer & Oncology Source Type: research
Apple 2019
Liver Cancer 2019;8:220 –220 (Source: Liver Cancer)
Source: Liver Cancer - May 17, 2019 Category: Cancer & Oncology Source Type: research
Pembrolizumab for the Treatment of Hepatocellular Carcinoma
Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - April 29, 2019 Category: Cancer & Oncology Source Type: research
Liver Transplant for Patients with Hepato cellular Carcinoma and Child-Pugh C Liver Function Should Be Mentioned in Guidelines
Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - March 31, 2019 Category: Cancer & Oncology Source Type: research
Sorafenib: Experience and Better Manage ment of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis
Conclusion: When comparing 2 periods of treatment in advanced HCC patients under sorafenib, duration of treatment and mOS were higher in the recent period. While mOS did not differ for patients who progressed, it was 2-fold higher in the recent period for those who had tumor control. Improvements in the use of sorafenib seem to be associated with better outcomes limited to patients with DC.Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - March 31, 2019 Category: Cancer & Oncology Source Type: research
